Interferon beta-1a - Biopartners GmbH/Rentschler

Drug Profile

Interferon beta-1a - Biopartners GmbH/Rentschler

Alternative Names: Biferonex; HSA-free IFN β-1a; Human serum albumin-free interferon beta

Latest Information Update: 12 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rentschler
  • Developer Biopartners GmbH
  • Class Antineoplastics; Interferons
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Multiple sclerosis

Most Recent Events

  • 31 Dec 2014 Biomarkers information updated
  • 30 May 2009 BioPartners withdraws the centralised marketing application for interferon beta-1a for Multiple sclerosis in European Union
  • 19 Feb 2009 The CHMP has issued a negative opinion regarding approval of interferon beta-1a for treatment of Multiple sclerosis in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top